Insider Selling: Natera Inc (NTRA) CTO Sells 118,463 Shares of Stock

Share on StockTwits

Natera Inc (NASDAQ:NTRA) CTO Jonathan Sheena sold 118,463 shares of the stock in a transaction dated Wednesday, March 20th. The stock was sold at an average price of $20.50, for a total transaction of $2,428,491.50. Following the transaction, the chief technology officer now directly owns 355,621 shares of the company’s stock, valued at $7,290,230.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Jonathan Sheena also recently made the following trade(s):

  • On Friday, March 22nd, Jonathan Sheena sold 190,286 shares of Natera stock. The stock was sold at an average price of $20.50, for a total transaction of $3,900,863.00.
  • On Wednesday, March 13th, Jonathan Sheena sold 23,356 shares of Natera stock. The stock was sold at an average price of $20.51, for a total transaction of $479,031.56.
  • On Monday, March 11th, Jonathan Sheena sold 3,043 shares of Natera stock. The stock was sold at an average price of $16.00, for a total transaction of $48,688.00.
  • On Monday, December 24th, Jonathan Sheena sold 507 shares of Natera stock. The stock was sold at an average price of $12.39, for a total transaction of $6,281.73.

Shares of Natera stock opened at $19.68 on Friday. Natera Inc has a 12-month low of $8.60 and a 12-month high of $29.62. The company has a debt-to-equity ratio of 2.28, a current ratio of 2.11 and a quick ratio of 2.32. The stock has a market capitalization of $1.29 billion, a price-to-earnings ratio of -9.15 and a beta of 1.84.

Natera (NASDAQ:NTRA) last issued its earnings results on Tuesday, March 12th. The medical research company reported ($0.51) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.51). Natera had a negative net margin of 49.72% and a negative return on equity of 790.13%. The company had revenue of $67.00 million during the quarter, compared to analysts’ expectations of $62.87 million. As a group, sell-side analysts predict that Natera Inc will post -2.24 earnings per share for the current year.

A number of institutional investors have recently modified their holdings of NTRA. FMR LLC purchased a new position in Natera in the third quarter valued at about $59,599,000. Vanguard Group Inc increased its holdings in Natera by 28.9% in the third quarter. Vanguard Group Inc now owns 3,612,860 shares of the medical research company’s stock valued at $86,493,000 after buying an additional 808,976 shares in the last quarter. Vanguard Group Inc. increased its holdings in Natera by 28.9% in the third quarter. Vanguard Group Inc. now owns 3,612,860 shares of the medical research company’s stock valued at $86,493,000 after buying an additional 808,976 shares in the last quarter. Renaissance Technologies LLC increased its holdings in Natera by 92.9% in the third quarter. Renaissance Technologies LLC now owns 1,528,400 shares of the medical research company’s stock valued at $36,590,000 after buying an additional 736,000 shares in the last quarter. Finally, BlackRock Inc. increased its holdings in Natera by 33.5% in the third quarter. BlackRock Inc. now owns 2,785,208 shares of the medical research company’s stock valued at $66,679,000 after buying an additional 698,379 shares in the last quarter. 89.44% of the stock is owned by institutional investors.

Several research analysts recently issued reports on NTRA shares. BidaskClub raised shares of Natera from a “strong sell” rating to a “sell” rating in a report on Friday, December 7th. ValuEngine cut shares of Natera from a “strong-buy” rating to a “buy” rating in a report on Wednesday, January 9th. Finally, Zacks Investment Research cut shares of Natera from a “hold” rating to a “sell” rating in a report on Thursday, January 10th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. Natera has a consensus rating of “Buy” and a consensus target price of $27.75.

COPYRIGHT VIOLATION WARNING: “Insider Selling: Natera Inc (NTRA) CTO Sells 118,463 Shares of Stock” was published by Zolmax and is the sole property of of Zolmax. If you are viewing this news story on another site, it was stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this news story can be read at https://zolmax.com/investing/insider-selling-natera-inc-ntra-cto-sells-118463-shares-of-stock/2986440.html.

About Natera

Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

Read More: What is the downside to momentum investing?

Insider Buying and Selling by Quarter for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

BUDDY Price Down 36.7% Over Last 7 Days
BUDDY Price Down 36.7% Over Last 7 Days
Zacks: Analysts Expect Regency Centers Corp  Will Post Quarterly Sales of $274.40 Million
Zacks: Analysts Expect Regency Centers Corp Will Post Quarterly Sales of $274.40 Million
Analysts’ Weekly Ratings Updates for Pentair
Analysts’ Weekly Ratings Updates for Pentair
Regent Investment Management LLC Has $972,000 Stake in Charles Schwab Co.
Regent Investment Management LLC Has $972,000 Stake in Charles Schwab Co.
Petroteq Energy   Shares Down 3.8%
Petroteq Energy Shares Down 3.8%
Winslow Evans & Crocker Inc. Sells 406 Shares of NVIDIA Co.
Winslow Evans & Crocker Inc. Sells 406 Shares of NVIDIA Co.


 
© 2006-2019 Zolmax.